Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma

New England Journal of Medicine

Volumn 369, Issue 2, 2013, Pages 134-144

  Hamid, Omid ^a   Robert, Caroline ^c   Daud, Adil ^d   Hodi, F Stephen ^e   Hwu, Wen Jen ^f   Kefford, Richard ^g   Wolchok, Jedd D ⁱ   Hersey, Peter ^h   Joseph, Richard W ^j   Weber, Jeffrey S ^k   Dronca, Roxana ^l   Gangadhar, Tara C ^m   Patnaik, Amita ⁿ   Zarour, Hassane ^o   Joshua, Anthony M ^p   Gergich, Kevin ^q   Elassaiss Schaap, Jeroen ^q   Algazi, Alain ^d   Mateus, Christine ^c   Boasberg, Peter ^a   Tumeh, Paul C ^b   Chmielowski, Bartosz ^b   Ebbinghaus, Scot W ^q   Li, Xiaoyun Nicole ^q   Kang, S Peter ^q   Ribas, Antoni ^b   more..

^a Angeles Clinic and Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF SYDNEY   (Australia)

^h MELANOMA INSTITUTE AUSTRALIA   (Australia)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j MAYO CLINIC   (United States)

^k H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ South Texas Accelerated Research Therapeutics   (United States)

^o UNIVERSITY OF PITTSBURGH   (United States)

^p PRINCESS MARGARET HOSPITAL   (Canada)

^q MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; GLUCOCORTICOID; IPILIMUMAB; LAMBROLIZUMAB; MK 3475; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE DISEASE; BRAIN METASTASIS; BRONCHOPNEUMONIA; BRONCHOSCOPY; CANCER PROGNOSIS; CAUSE OF DEATH; CHILL; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; CYTOTOXIC T LYMPHOCYTE; DECREASED APPETITE; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOCRINE DISEASE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNE RESPONSE; INFLAMMATORY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIMIT OF QUANTITATION; LUNG BIOPSY; LUNG INFILTRATE; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL METASTASIS; VITILIGO;

EID: 84879759020     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1305133     Document Type: Article

References (17)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
4. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004;64:1140-5. (Pubitemid 38176921)
5. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813-24. (Pubitemid 47241890)
6. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366:2517-9.
7. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
8. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
10. Patnaik A, Kang SP, Tolcher AW, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2012; 30:Suppl:2512. abstract.
11. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
13. CTCAE v4. 2013 (http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htm).
14. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003;21:2415-32. (Pubitemid 46621880)
15. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16. (Pubitemid 29318842)
16. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-ofcare chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22.
17. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6. (Pubitemid 26102823)